- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Improving Clinician Awareness and Adoption of Molecular Testing
A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve clinician awareness and adoption of molecular testing in community oncology settings while acknowledging that some effective treatments work across patient populations without requiring biomarker stratification.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients
EP: 12.Single-Agent Vs Combination Regimens
EP: 13.The Potential Impact of Investigational Therapies
EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer
Video content above is prompted by the following:
Improving Clinician Awareness and Adoption in Community Settings
Strategies to improve molecular testing adoption in community oncology include the following:
- Enhanced educational initiatives for physicians
- Greater reliance on guidelines like NCCN, which provide flexibility in clinical application
- Improved reimbursement policies that incentivize evidence-based care
- Recognition that although biomarker-directed therapy is important, treatments that work across all patients (biomarker-agnostic) remain valuable
Recent examples of non–biomarker-directed advances include relacorilant (cortisol blocker) with nab-paclitaxel showing improved progression-free survival and overall survival in platinum-resistant ovarian cancer, and tisotumab vedotin (targeting tissue factor) in cervical cancer.
Collaboration between academic and community settings, participation in clinical research, and tissue collection for biomarker discovery remain essential for continued progress in treatment personalization.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
